Alto Neuroscience, Inc. (ANRO) shares gained 8.81 percent to $24.22, rising $1.96 on Monday, after the company reported annual results and announced a $120 million private placement financing.
The stock is currently trading at $24.22 compared with its previous close of $22.26. Shares opened at $22.52 and traded between $21.76 and $24.70 during the session on the New York Stock Exchange. Trading volume reached about 264,073 shares, in line with the average volume of about 261,513 shares.
Alto Neuroscience reported a 2025 net loss of $63.2 million, or $2.19 per share, compared with a net loss of $61.4 million, or $2.50 per share, in 2024. Operating expenses declined to $66.4 million from $68.6 million.
Separately, the company said the private placement financing will support development of ALTO-207, including a planned Phase 3 trial in treatment-resistant depression, with pro forma cash estimated at about $275 million as of February 28, 2026.
The stock has traded in a 52-week range of $1.60 to $24.70.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.